| Literature DB >> 36268123 |
Mariachiara Micaelli1, Andrea Dalle Vedove1, Linda Cerofolini2,3, Jacopo Vigna4, Denise Sighel1, Sara Zaccara5, Isabelle Bonomo1, Georgios Poulentzas1, Emanuele Filiberto Rosatti1, Giulia Cazzanelli1, Laura Alunno1, Romina Belli6, Daniele Peroni6, Erik Dassi1, Shino Murakami5, Samie R Jaffrey5, Marco Fragai2,3, Ines Mancini4, Graziano Lolli1, Alessandro Quattrone1, Alessandro Provenzani1.
Abstract
YTHDF proteins bind the N 6-methyladenosine (m6A)-modified mRNAs, influencing their processing, stability, and translation. Therefore, the members of this protein family play crucial roles in gene regulation and several physiological and pathophysiological conditions. YTHDF proteins contain a hydrophobic pocket that accommodates the m6A embedded in the RRACH consensus sequence on mRNAs. We exploited the presence of this cage to set up an m6A-competitive assay and performed a high-throughput screen aimed at identifying ligands binding in the m6A pocket. We report the organoselenium compound ebselen as the first-in-class inhibitor of the YTHDF m6A-binding domain. Ebselen, whose interaction with YTHDF proteins was validated via orthogonal assays, cannot discriminate between the binding domains of the three YTHDF paralogs but can disrupt the interaction of the YTHDF m6A domain with the m6A-decorated mRNA targets. X-ray, mass spectrometry, and NMR studies indicate that in YTHDF1 ebselen binds close to the m6A cage, covalently to the Cys412 cysteine, or interacts reversibly depending on the reducing environment. We also showed that ebselen engages YTHDF proteins within cells, interfering with their mRNA binding. Finally, we produced a series of ebselen structural analogs that can interact with the YTHDF m6A domain, proving that ebselen expansion is amenable for developing new inhibitors. Our work demonstrates the feasibility of drugging the YTH domain in YTHDF proteins and opens new avenues for the development of disruptors of m6A recognition.Entities:
Year: 2022 PMID: 36268123 PMCID: PMC9578143 DOI: 10.1021/acsptsci.2c00008
Source DB: PubMed Journal: ACS Pharmacol Transl Sci ISSN: 2575-9108